ResearcherUniversité de MontpellierActive in the last 2 years

Irene Conforti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4602-6594; OpenAlex author ID A5039914534. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents. Co-author DOI 10.2174/0115734064289584240121142405 ↗
Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents. Co-author DOI 10.3390/pharmaceutics15051472 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Alessio Nencioni · 2 shared papers, 2023–2024 · strength 0.48
- Paper New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents. DOI 10.2174/0115734064289584240121142405 ↗
- Paper Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents. DOI 10.3390/pharmaceutics15051472 ↗
Alberto Marra · 2 shared papers, 2023–2024 · strength 0.48
- Paper New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents. DOI 10.2174/0115734064289584240121142405 ↗
- Paper Iminosugar-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Anti-Pancreatic Cancer Agents. DOI 10.3390/pharmaceutics15051472 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.